Krishnan et al. [39] found that in TCGA of clear cell renal carcinoma, the AA cohort has a lower mutation rate of the tumour suppressor gene VHL and a correspondingly lower level of HIF-1α/VEGF pathway activation, explaining the resistance of these patients to the commonly used VEGF-targeted therapies. This evidence concerns the gene VEGFA and clear cell renal carcinoma.